1. |
邓蓉, 梁燕, 谭小波, 等. 强直性脊柱炎患者自我管理状况调查分析. 华西医学, 2015, 30(1): 115-118.
|
2. |
Semb AG, Kvien TK, Demicco DA, et al. Prediction of cardiovascular events in patients with ankylosing spondylitis and psoriatic arthritis: role of lipoproteins in a high-risk population. J Rheumatol, 2012, 39(7): 1433-1440.
|
3. |
Atzeni F, Corda M, Sarzi-Puttini P, et al. From old to new cardiovascular complications in ankylosing spondylitis. Isr Med Assoc J, 2017, 19(8): 506-509.
|
4. |
Mathieu S, Gossec L, Dougados M, et al. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken), 2011, 63(4): 557-563.
|
5. |
Lin FJ, Tseng WK, Yin WH, et al. Residual risk factors to predict major adverse cardiovascular events in atherosclerotic cardiovascular disease patients with and without diabetes mellitus. Sci Rep, 2017, 7(1): 9179.
|
6. |
Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun, 2014, 48-49(1): 128-133.
|
7. |
Wang G, Pierangeli SS, Willis R, et al. Significance of lipid-derived reactive aldehyde-specific immune complexes in systemic lupus erythematosus. PLoS One, 2016, 11(10): e0164739.
|
8. |
Djoković A, Stojanović L. Cardiac manifestations in antiphospholipid syndrome. A brief review of the literature. Srp Arh Celok Lek, 2015, 143(5/6): 346-353.
|
9. |
中华医学会心血管病学分会, 中国老年学学会心脑血管病专业委员会. 血脂相关性心血管剩余风险控制的中国专家共识. 中华心血管病杂志, 2011, 40(1): 547-553.
|
10. |
Machado D, Sarni RO, Abad TT, et al. Lipid profile among girls with systemic lupus erythematosus. Rheumatol Int, 2017, 37(1): 43-48.
|
11. |
Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum, 2009, 38(5): 372-381.
|
12. |
吴智鸿, 赵水平. 类风湿关节炎与冠心病. 中华风湿病学杂,2004, 8(11): 688-690.
|
13. |
Yeh ET. CRP as a mediator of disease. Circulation, 2004, 109(21, S): 11-14.
|
14. |
Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol, 2006, 33(3): 539-545.
|
15. |
Heslinga SC, Peters MJ, Ter Wee MM, et al. Reduction of inflammation drives lipid changes in ankylosing spondylitis. J Rheumatol, 2015, 42(10): 1842-1845.
|
16. |
Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum, 2012, 64(1): 285-296.
|
17. |
Mathieu S, Dubost JJ, Tournadre A, et al. Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis. Joint Bone Spine, 2010, 77(1): 50-52.
|